Episode Details

ICON plc (ICLR) Q2 2026 — ICON reported Q2 2026 (quarter ended June 30) after the close on July 29. Revenue $2,063.5M (+1.2%, +0.4% cc), adjusted EPS $2.56 vs $3.52 (-27.3%), adjusted EBITDA $327.2M / 15.9% (from 20.5%). Net book-to-bill 1.51x on gross bookings +24.1%. The stock went $178.18 -> $165.53 -> $163.57: about -8.2% in two sessions. The 1.51x book-to-bill was called 'optically a crazy high number throughout the entire history of the industry' on the call — but ICON's own release says the DIRECT FEE book-to-bill was 1.20x, and its 2026 guide assumes direct fee revenue DECLINES ~2% organically. Worse: gross profit DOLLARS fell $104.0M (-17.8%) on revenue that rose, which a pass-through mix shift cannot arithmetically explain. THE CALL: REDUCE (3/5, A REAL BACKLOG, A BROKEN MARGIN, A PRICED RECOVERY) — base-case value ~$125.0 vs ~$163.57 today. KEY METRICS: - OUR CALL: REDUCE 3/5 — fair value ~$125 vs the $163.57 close (-24%). Street: Buy but with NO upside — consensus target $164.75 (+0.7%) across 30 analysts (17 buy/11 hold/2 sell), range $100-$207. Post-print upgrades: Truist to Buy $207 (from $159), RBC to Outperform $185 (from $126), Mizuho $190. - THE PRINT: revenue $2,063.5M (+1.2%, +0.4% constant currency). Adjusted diluted EPS $2.56 vs $3.52 (-27.3%). Adjusted EBITDA $327.2M = 15.9% of revenue vs 20.5% (-21.7%). GAAP diluted EPS $0.94 vs $2.56 — a $32.9M loss on the Symphony Health disposal plus a ~$40M swing on the tax line. Effective tax rate 18.4%. - THE 1.51x THAT ISN'T: gross bookings $3,681M (+24.1%), cancellations $562M, net wins $3,120M, net book-to-bill 1.51x, backlog $23.4B (+3.0% q/q). But the DIRECT FEE book-to-bill was 1.20x (1.3x in Q1, ~1.25x for H1). Pass-throughs (investigator grants, site fees, imaging, patient travel) are reimbursed at ~zero margin. Management blames US healthcare inflation, not demand. - THE GUIDE NOBODY QUOTES: at the midpoint, ICON's own 2026 outlook assumes DIRECT FEE revenue declines ~2% organically. FY guide $7,850-8,150M revenue and $10.00-11.00 adjusted EPS — vs $8,251.3M and $12.53 in 2025 and $13.37 in 2024. Guide midpoint implies ~16.5% full-year EBITDA margin. - THE $104M MIX CANNOT EXPLAIN: revenue $2,039.1M -> $2,063.5M, but direct costs $1,455.8M -> $1,584.2M (+8.8%). Gross profit fell $583.3M -> $479.3M: -$104.0M, -17.8%. Adjusted gross margin 23.8% from 29.1% (-530bps). A pass-through shift lowers the margin PERCENT and leaves gross profit DOLLARS unchanged — so it cannot account for a dollar decline. - FIVE QUARTERS OF ADJUSTED EPS: $3.52 (Q2'25) -> $3.22 (Q3'25) -> $2.52 (Q4'25) -> $2.50 (Q1'26) -> $2.56 (Q2'26). Adjusted EBITDA: ~$1,671M (2024) -> $1,530.7M (2025) -> ~$1,320M implied (2026) = -21% in two years. - THE RESTATEMENT: Feb 12, 2026 the Audit Committee investigation was disclosed and the stock fell 39.8% in one session on 23.6M shares. Concluded April 27: revenue OVERSTATED 0.8% in 2023 and 1.1% in 2024 (smaller in 2025). Two 20-Fs and eleven quarterly 6-Ks declared non-reliable. Material weaknesses disclosed. Nasdaq deficiency notice May 19; cured May 27. Q4'25, Q1'26 and Q2'26 all reported in nine weeks. - WHAT IT COST: 'transaction, integration related and other' was $24.7M in the quarter and $56.1M in H1 vs $12.1M in H1 2025 — investigation costs, out-of-scope audit fees and defence of a putative securities class action, all added back to adjusted earnings. Buyback: $0 in H1 2026 vs $500M in H1 2025; management says it restarts in Q3 — at $163 rather than the $80-120 it sat out. - BALANCE SHEET: cash $928.4M (from $390.4M), total debt $3.39B, net debt $2.46B = 1.8x adjusted EBITDA. But $1.28B of debt is now CURRENT (from $529.8M). FCF $238.9M in the quarter, $375.1M in H1, $862.0M in 2025. Goodwill $8.72B + intangibles $3.15B = 72% of $16.4B total assets, almost all from the 2021 PRA Health Sciences deal. - OWNER EARNINGS: guided 2026 adj. EBITDA ~$1,320M, less $95M SBC, $60M recurring restructuring, $15M residual investigation cost, $160M ca